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ZoledronateAbstract Even though increasing knowledge is emerging about synovitis, acne, pustulosis, hyper-
ostosis and osteitis (SAPHO) syndrome its pathogenesis remains enigmatic. Women are preferen-
tially affected by SAPHO syndrome. Here we present the case of a 39-year-old woman suffering
from this syndrome whose bone involvement was ﬁrst interpreted as diffuse sclerosing osteomyelitis
of the mandible. As treatment with clindamycin did not improve the symptoms, the decision was
made to administer bisphosphonates intravenously. This treatment led to a rapid improvement
in symptoms, which could be explained by the apparent tendency of bisphosphonates to exert a pos-
itive effect on the jaw. With this case report we attempt to offer an explanation for the inﬂuence of
this group of medications on patients suffering from SAPHO syndrome with mandibular involve-
ment.
ª 2015 Tehran University of Medical Sciences. Published by Elsevier Ltd. This is an open access article
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Synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO)
syndrome was ﬁrst described by Chamot et al. in 1987 [1]. To
date its etiology has remained unknown [2–5] SAPHO syn-
drome is a rheumatic disease belonging to the group of
spondyloarthropathies and combining osteomyelitis, osteitis,
arthritis and skin disease [1,5–9]. Its diagnosis can be made
with the aid of three diagnostic criteria classiﬁed by Kahn
et al. [10] (Table 1).
The prevalence of SAPHO syndrome is approximately
1:10,000 and is more likely to occur in females [2,9]. It usually
has an early onset, with the ﬁrst symptoms mainly arising dur-
ing childhood or young adulthood [2,3,9]: these symptoms
manifest themselves as characteristic lesions of the bone, skin
and skin appendages [1,3,8–10]. The most commonly affected
bones are the clavicle and the sternum, but manifestations
can also be seen on long tubular and tarsal bones, as well as
the spine and ribs [2,3,8,9]. Involvement of the mandible has
also been described in approximately 10% of cases [2,4,9,11].
However, as the bone and skin lesions, like palmoplantar pus-
tulosis, do not necessarily emerge at the same time, making an
appropriate diagnosis of the syndrome can be difﬁcult and
challenging [9,12].
In addition, the bone lesions can resemble those occurring
in chronic recurrent multifocal osteomyelitis [13] or in diffuse
sclerosing osteomyelitis of the mandible [13,14], causing
SAPHO syndrome to easily be misdiagnosed as nonsuppura-
tive chronic inﬂammation [14]. In its acute phase, the lesion
can be indistinguishable from suppurative osteomyelitis
[5,6,12]. Therefore, in both scenarios, patients are treated with
antibiotics upon the ﬁrst instance of the lesion and receive
additional surgical therapy, such as decortication and partial
resection of the affected bones. This treatment regime does
not usually lead to the desired results and does not cure
SAPHO syndrome in the long run [5,12,14].
Another group of pharmaceuticals, the nitrogen-containing
bisphosphonates, has proved to be effective in easing pain and
preventing progression in several recent publications [3,7,14–16].
Nevertheless, as only a limited number of patients suffer from
SAPHO syndrome, to our knowledge no clinical long-term
follow-up studies with a large patient population have been
performed. Hence, no ofﬁcial guideline for drug treatment has
been established to date. Recent studies demonstrated a relief of
jaw symptoms after affected patients received bisphosphonates
[3,7,14], an observation thatmay offer a possible explanation for
the etiology of SAPHO syndrome.
The following case report describes a 39-year-old woman
with SAPHO syndrome, which was initially suspected to be
a diffuse sclerosing osteomyelitis of the right mandible and
was therefore treated with antibiotics at the beginning. With
this case report we describe the clinically successful treatmentTable 1 Diagnostic criteria for SAPHO syndrome according to Kh
Chronic recurrent osteomyelitis ﬁ Sterile or with presenc
ﬁ With or without skin l
ﬁ Possible spine involvem
Acute, subacute or chronic arthritis ﬁ With any of the follow
Osteitis ﬁ With any of the followof a SAPHO patient with bisphosphonates that led to reduc-
tion in pain and the accompanying swelling. Due to the local-
ization of the affected tissues and the fast pain relief following
administration of this medication, we also outline a possible
hypothesis about the mechanism of this positive effect.
Case report
A 39-year-old woman presented at the Oral and Maxillofacial
Surgery out-patient department of the University of Erlangen
in June 2012 after being referred from the Rheumatology
Department. She described a recurring swelling of the right
sub- and paramandibular region accompanied by severe pain.
Her ability to open her mouth was restricted during these peri-
ods. According to the patient, the mandibular pain started the
year before, in May 2011 and she made an appointment with
her dentist from whom she received an apicectomy of the lower
right second premolar and lower right ﬁrst molar in combina-
tion with antibiotic therapy. This treatment was not successful,
as the patient had a relapse of symptoms.
The patient was then referred to another dentist, who diag-
nosed a myopathy and thus commenced with splint therapy.
The complaints persisted, which led to her visiting another
dentist at the beginning of 2012: the lower right second premo-
lar, the lower right ﬁrst molar and the lower right second
molar were extracted and a bone biopsy was taken from the
same region. As bacterial osteomyelitis was suspected, antibi-
otic therapy with clindamycin (1.2 g per day) was carried out
for a month. This regime did not improve the symptoms,
and neither did the administration of corticosteroids (30 mg
per day, with slow tapering of dosage) for three months.
Histological examination of the bone biopsy revealed chronic
inﬂammation signs that were consistent with sterile
osteomyelitis. This observation led to her referral to the
Rheumatology Department of the University Hospital in
Erlangen in June 2012, as the woman was known to have
SAPHO syndrome.
The patient indicated that the initial symptoms of SAPHO
syndrome arose when she was approximately 12 years of age as
skin lesions in the form of palmoplantar psoriasis. A few years
later, at the end of her teens, she noticed spinal pain on the left
side, which was ﬁrst thought to be of renal origin. This possi-
bility was excluded by medical tests performed at that time.
Approximately 10 years later, at the end of her twenties, the
patient started complaining of pain in her sternal region. As
a result of the bone manifestations and the palmoplantar
lesions, SAPHO syndrome was diagnosed.
The Rheumatology Department referred the patient to our
out-patient department in order to exclude any possible dental
foci before initiating bisphosphonate therapy. No oral inﬂam-
matory or suppurative lesions were diagnosed clinically or
radiologically. Two separate orthopantomograms werean et al.
e of Propionibacterium acnes
esions
ent
ing skin lesions: palmoplantar pustulosis, acne or pustular psoriasis
ing skin lesions: palmoplantar pustulosis, acne or pustular psoriasis
74 P. Gorecki et al.utilized for assessment. The ﬁrst orthopantomogram was taken
on 22nd November 2011 and showed apical radiolucencies of
the lower right ﬁrst molar and the lower right second premolar
(Fig. 1a). A second orthopantomogram taken on 13th June
2012 after the previously described tooth extractions revealed
slightly sclerotic extraction sockets in the right mandible
(Fig. 1b). A Pain and Thermal Sensitivity Test [17] was per-
formed, which demonstrated normal site-to-site variation in
warm and cold sensation detection thresholds between the
right and left mandibular nerves.
Since a histopathological examination had already been
performed by the patient’s dentist, and during our assessment
we observed no pathologies clinically or radiologically, there
was no indication for surgical intervention at that time. Bone
scintigraphy was carried out to identify possible additional
bone lesions and magnetic resonance imaging (MRI) was per-
formed. Bone scintigraphy revealed signs of osteitis in the right
mandible and in the sternum, as well as sacroiliitis, all of which
are typical of SAPHO syndrome (Fig. 2). Fat-saturated T1-
weighted MRI of the jaw showed decreased signal intensity,
and fat-saturated T2-weighted MRI displayed increased signal
intensity in and around the mandible along with an increased
contrast medium uptake in the inﬂamed bone, which was inter-
preted as bone marrow edema (Fig. 3).
Due to these ﬁndings and non-effective antibiotic treat-
ment, we initiated therapy with zoledronic acid, a bisphospho-
nate. The patient described fever-like symptoms, that lasted for
two days and generalized aches and pains for four days after
the initial intravenous dose of 5 mg: these are known side
effects of bisphosphonate therapy [13,14,18]. After remission
of these symptoms, the patient described nearly complete relief
of mandibular complaints. One month after the ﬁrst bisphos-
phonate administration, no relapse of previous clinical symp-
toms was observed. In contrast, skin manifestations did not
change following bisphosphonate treatment. Follow-up MRI
performed three weeks after therapy initiation showed no rel-
evant changes, which was not in accordance with the clinical
ﬁndings stated above (Fig. 4).
Hypotheses
The etiology of SAPHO syndrome remains unknown [2–4],
and as result its treatment is empirical and symptomaticFig. 1 Images of orthopantomograms performed on 22nd November
apical radiolucencies of the lower right ﬁrst molar and the lower rig
slightly sclerotic extraction sockets in the right mandible.[3,4,6,9]. Although various case reports have been published,
no consensus has been reached concerning guidelines for ideal
therapy [2,4,9,14].
First choice treatment includes non-steroidal anti-inﬂam-
matory drugs (NSAIDs) and other analgesics [4,6,13].
Unfortunately, their use is accompanied by limited efﬁcacy
[4,6,14], and thus other therapeutic agents need to be identiﬁed
to achieve long-term relief for the affected.
Antibiotics have been tried in various studies. Due to the
isolation of Propionibacterium acnes in bone biopsies of some
SAPHO patients, this treatment option seems to be reasonable
[4,6,19–22]. In most cases, antibiotics fail to achieve clinical
improvement [4,6,8] and it has thus been assumed that P. acnes
may act as an antigen that triggers an immunological response
and leads to inﬂammation [4,6,20].
The administration of anti-tumor-necrosis-factor-alpha
(anti-TNF-alpha) drugs seems promising. Although a positive
effect has been reported in various studies, especially in refrac-
tory cases [6,23], their use is rather costly and many side effects
have been described, including infections, worsening of heart
disease and neuropathies [6,14].
In our case report, we administered another group of med-
ication, bisphosphonates, which have been shown to display
less severe side effects. Bisphosphonates are usually adminis-
tered to patients suffering from various types of cancer, for
example of the breast or prostate, to prevent bone metastasis
or to patients suffering from osteoporosis. These pharmaceuti-
cals appear to be a logical treatment option for SAPHO
patients, as they exert both an anti-osteoclastic effect (by
prompting apoptosis of osteoclasts) and an anti-inﬂammatory
effect [3,7,18,24–26]. Osteoclastogenesis is promoted by pro-in-
ﬂammatory cytokines such as interleukin-1 (IL-1) or tumor-
necrosis-factor-alpha (TNF-alpha) by enhancing signaling of
receptor activator of the nuclear factor jB ligand (RANKL)
[24–26]. Conversely, bisphosphonates induce an anti-inﬂam-
matory response by suppressing these cytokines, which results
in less inﬂammation and decreased pain sensation [3,7,18]. A
positive effect on various rheumatological conditions has
already been conﬁrmed [3,6,7,18].
Numerous studies have illustrated the impact of bisphos-
phonates on osteoblasts and osteoclasts by inﬂuencing gene
function. One of the affected proteins is the neural crest-related
and osteoproliferative transcription factor MSX-1, which is2011 (a) and 13th June 2012 (b). (a) The ﬁrst examination revealed
ht second premolar. (b) The second orthopantomogram showed
Fig. 1 (continued)
Fig. 2 Bone scintigraphy performed before initiation of treatment with bisphosphonates. Blood pool images of the whole body from
ventral (a) and dorsal (b) views and delayed images of the whole body from ventral (c) and dorsal (d) views and of the skull from the left
(e) and right (f) conﬁrm signs of osteitis of the sternum, the sternoclavicular (SC) joint and the costosternal joint. These lesions can be
interpreted as the so-called ‘‘bull head’s sign’’ and are characteristic of SAPHO syndrome. Highly increased tracer uptake in the right
ventrolateral mandibular bone is recognizable, as well as slightly increased tracer uptake in both iliosacral joints.
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Fig. 3 MRI before initiation of bisphosphonate therapy with zoledronic acid. (a) Native axial T1-weighted MRI before the application
of contrast medium. Bone marrow signal, which should be hyperintense on T1w images, exhibited decreased signal intensity in the right
mandible compared to the other side. (b) Coronal fat-saturated T2-weighted MRI shows increased signal intensity in the right mandible.
(c) Axial fat-saturated T1-weighted MRI after administration of a contrast agent reveals decreased signal intensity in the right mandible
due to the application of fat suppression, as well as increased contrast medium uptake in the inﬂamed bone and the adjacent soft tissue.
Fig. 4 Follow-up MRI one month after initiation of bisphosphonate therapy with zoledronic acid. (a) Native axial T1-weighted MRI
before a contrast agent was applied. Bone marrow signal remained decreased. (b) Coronal fat-saturated T2-weighted MRI indicates
increased signal intensity in the right mandible. (c) Axial fat-saturated T1-weighted MRI with contrast agent administration. The slice
shows decreased signal intensity in the right mandible due to the application of fat suppression and increased contrast medium uptake in
the inﬂamed bone and the adjacent soft tissue.
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nently expressed in the jaw bone [27,28]; in contrast, MSX-1
downregulation in mesenchymal cell-derived tissues has been
observed. Temporary reactivation of MSX-1 has been identi-
ﬁed, for example during wound healing [15]. Impaired function
and decreased expression of MSX-1 were previously demon-
strated in tissues of bisphosphonate-related osteonecrosis of
the jaw (BRONJ) in vivo, providing a possible explanation of
why BRONJ is restricted to the jaw bone [27,28].
All tissues affected in SAPHO patients derive from neural
crest cells; even the clavicle and the sternum originate partly
from neural crest cells [29]. Therefore, bisphosphonates may
modulate osteoblasts by inﬂuencing MSX-1, among other pro-
teins, and contribute to relief of symptoms by exerting osteo-
genic effects and increasing bone density. Moreover, the
relation between bisphosphonate administration and MSX-1expression may help to identify a possible explanation for
the etiology of SAPHO syndrome. Impaired function of tran-
scription factors like MSX-1 may underlie the appearance of
the syndrome and may lead to the identiﬁcation of additional
genes involved in the progress of SAPHO syndrome.
Evaluation of hypotheses
In accordance with this hypothesis, the use of bisphosphonates
in SAPHO patients has achieved positive results to date.
Amital et al. [7], Kerrison et al. [16], Solau-Gervais et al. [30]
and Colina et al. [31] effectively treated patients with pamidro-
nate. Hatano et al. [14] reported a relief of symptoms after
administration of risedronate in combination with pred-
nisolone. Kopterides et al. [3] demonstrated a successful ther-
apy with zoledronic acid in a patient with SAPHO syndrome
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alone had restricted efﬁcacy.
We chose zoledronic acid for our patient because her
SAPHO syndrome was resistant to antibiotic therapy and
because zoledronic acid has greater potency and better renal
tolerability than pamidronate. Gastrointestinal side effects
are also avoided, as zoledronate bypasses the gastrointestinal
tract [3,18]. Our case report conﬁrms the conclusion of earlier
studies that bisphosphonates are an effective treatment for
patients suffering from SAPHO syndrome with mandibular
involvement. Fever-like side effects were observed here, but
our patient emphasized the reduction of pain in the right lower
jaw and the reduction of the associated swelling.
In contrast to our clinical ﬁndings and the relief of symp-
toms described by our patient, no improvement was detected
in the follow-up MRI. This lack of change has also been
described in earlier studies [13]. Changes in bone density take
a longer time to be detectable by MRI, as this method is less
sensitive to inﬂammatory changes. Nonetheless, MRI is a
safe and adequate method that causes no exposure to
radiation [13].
As our case report concentrates on clinical ﬁndings, we
selected the follow-up period reported here. This case report
emphasizes that rapid and permanent clinical improvement
can be achieved by the administration of bisphosphonates to
patients with SAPHO syndrome, although this effect did not
extend to radiological ﬁndings. In order to evaluate the possi-
ble etiology proposed in this report, further studies are needed
to assess the role of MSX-1 and neural crest-derived tissues in
the development of SAPHO syndrome and to clarify its etiol-
ogy. For this purpose, it should be investigated whether MSX-
1-related signaling is involved in tissues affected by SAPHO
syndrome.
Conclusion
Drug therapy remains the recommended treatment option
for patients with SAPHO syndrome, as surgical intervention
has failed to show success and does not automatically lead
to a cure of SAPHO syndrome. Apart from analgesic
agents, antibiotics and bisphosphonates are the most efﬁ-
cient treatment modalities to date. The latter pharmaceuti-
cals are promising because they have led to the
improvement of symptoms in SAPHO patients, especially
in mandibular lesions.
The exact mechanism of bisphosphonate function remains
unknown. Studies that revealed a link between impaired func-
tion of the transcription factor MSX-1 and the development of
a BRONJ, may also offer a possible explanation for the
appearance of SAPHO syndrome, as the same pathway may
be affected. This hypothesis is supported by the observation
that tissues affected by SAPHO syndrome originate from the
same embryonic structures, the neural crest cells, and adminis-
tration of bisphosphonates results in the relief of symptoms in
affected tissues. This hypothesis needs to be validated by fur-
ther studies to identify the underlying causes of the condition.
The identiﬁcation of new and more accurate therapeutic
options in addition to antibiotics and bisphosphonates may
reveal a more precise approach for treating patients suffering
from SAPHO syndrome.Overview Box
First Question: What do we already know about the
subject?
The synovitis, acne, pustulosis, hyperostosis and ostei-
tis (SAPHO) syndrome belongs to the group of rheumatic
diseases and involves lesions of the bone, skin and skin
appendages. Its pathogenesis remains unknown up to
the present day, but bisphosphonates seem to inﬂuence
the syndrome’s progression positively.
Second Question: What does your proposed theory add
to the current knowledge available, and what beneﬁts does
it have?
The hypothesis presented in this paper proposes a
potential explanation for the yet unidentiﬁed etiology of
SAPHO syndrome. Impaired function of transcription
factors like MSX-1 could play a crucial role in its develop-
ment and bisphosphonates might improve symptoms by
modulating their response.
Third Question: Among numerous available studies,
what special further study is proposed for testing the idea?
As the prevalence of SAPHO syndrome is estimated to
be only 1:10,000, no clinical trials with a signiﬁcant
amount of patients have been carried out. Hence both
in vitro and in vivo studies are key to investigate the pro-
posed hypothesis further.Conﬂict of interest
There is nothing to disclose.
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